The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer;Le point de vue du biologiste sur la pharmacogénétique dans le cancer colorectal

Bulletin du Cancer

Volumn 95, Issue 10, 2008, Pages 935-942

  Laurent Puig, Pierre ^a   Lièvre, Astrid ^a   Ducreux, Michel ^b   Loriot, Marie Anne ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

Colorectal cancer; DYPD; KRAS; Pharmacogenetics; Pharmacogenomics; TYMS; UGT1A1

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; RITUXIMAB; THYMIDYLATE SYNTHASE;

COLORECTAL CANCER; DIARRHEA; DNA POLYMORPHISM; DRUG EFFICACY; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; NEUTROPENIA; REVIEW; TREATMENT RESPONSE; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CYCLIN D1; DIHYDROURACIL DEHYDROGENASE (NADP); EPIDERMAL GROWTH FACTOR; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HUMANS; MUTATION; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTORS, IGG; THYMIDYLATE SYNTHASE;

EID: 56149112380     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0728     Document Type: Review

References (57)

1. Beutler E. Study of glucose-6-phosphate dehydrogenase : history and molecular biology. Am J Hematol 1993 ; 42 : 53-8.
2. Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med 2003 ; 349 : 996-8.
3. Loriot MA, Beaune P. [Pharmacogenomics : the link between genes and response to drugs]. Med Sci (Paris) 2004 ; 20 : 634-6.
4. Evans WE, McLeod HL. Pharmacogenomics : drug disposition, drug targets, and side effects. N Engl J Med 2003 ; 348 : 538-49.
5. Tan BR, McLeod HL. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Semin Oncol 2005 ; 32 : 113-9.
6. McLeod HL, Watters JW. Irinotecan pharmacogenetics : is it time to intervene? J Clin Oncol 2004 ; 22 : 1356-9.
7. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil : mechanisms of action and clinical strategies. Nat Rev Cancer 2003 ; 3 : 330-8.
8. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999 ; 58 : 310-2.
9. Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 2001 ; 7 : 4096-101.
10. Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001 ; 19 : 1779-86.
11. Etienne MC, Chazal M, Laurent-Puig P, Magne N, Rosty C, Formento JL, et al. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy : phenotypic and genotypic analyses. J Clin Oncol 2002 ; 20 : 2832-43.
12. Marsh S, McKay JA, Cassidy J, McLeod HL. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001 ; 19 : 383-6.
13. Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001 ; 1 : 65-70.
14. Iacopetta B, Grieu F, Joseph D, Elsaleh H. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001 ; 85 : 827-30.
15. Lecomte T, Ferraz JM, Zinzindohoue F, Loriot MA, Tregouet DA, Landi B, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer parients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004 ; 10 : 5880-8.
16. Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004 ; 14 : 319-27.
17. Terrazzino S, Agostini M, Pucciarelli S, Pasetto LM, Friso ML, Ambrosi A, et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 2006 ; 16 : 817-24.
18. Etienne MC, Formento JL, Chazal M, Francoual M, Magne N, Formento P, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004 ; 14 : 785-92.
19. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer : a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003 ; 9 : 1611-5.
20. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992 ; 52 : 2899-902.
21. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006 ; 5 : 2895-904.
22. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004 ; 22 : 23-30.
23. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998 ; 101 : 847-54.
24. Santos A, Zanetra S, Cresteil T, Deroussent A, Pein F, Raymond E, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000 ; 6 : 2012-20.
25. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999 ; 65 : 576-82.
26. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995 ; 333 : 1171-5.
27. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004 ; 22 : 1382-8.
28. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity : a pharmacogenetic analysis. Cancer Res 2000 ; 60 : 6921-6.
29. Stewart CF, Panetta JC, O'Shaughnessy MA, Throm SL, Fraga CH, Owens T, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007 ; 25 : 2594-600.
30. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia : dose matters. J Natl Cancer Inst 2007 ; 99 : 1290-5.
31. Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007 ; 13 : 3269-75.
32. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001 ; 19 : 4298-304.
33. Park DJ, Sroehlmacher J, Lenz HJ. Tailoring chemotherapy in advanced colorectal cancer. Curr Opin Pharmacol 2003 ; 3 : 378-85.
34. Le Morvan V, Smith D, Laurand A, Brouste V, Bellott R, Soubeyran I, et al. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients : relationships with treatment outcome. Pharmacogenomics 2007 ; 8 : 1693-703.
35. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA. Human glutathione S-transferase P1 polymorphisms : relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 1998 ; 19 : 275-80.
36. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002 ; 94 : 936-42.
37. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer : a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002 ; 20 : 3478-83.
38. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemothetapy. Clin Cancer Res 2006 ; 12 : 3050-6.
39. Lièvre A, Laurent-Puig P. [Predictive factors of response to anti-EGFR treatments in colorectal cancer]. Bull Cancer 2008 ; 95 : 133-40.
40. Zhang W, Gordon M, Press OA, Rhodes K, Vallbohmer D, Yang DY, et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006 ; 16 : 475-83.
41. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002 ; 359 : 397-401.
42. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001 ; 276 : 6591-604.
43. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003 ; 21 : 3940-7.
44. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005 ; 23 : 474-81.
45. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007 ; 25 : 3712-8.
46. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004 ; 304 : 554.
47. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis : RAF/RAS oncogenes and mismatch-repair status. Nature 2002 ; 418 : 934.
48. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006 ; 66 : 3992-5.
49. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer : a cohort study. Lancet Oncol 2005 ; 6 : 279-86.
50. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutation is an independant prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2007 ; (in press).
51. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007 ; 67 : 2643-8.
52. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA : implications for chemosensitiviry and resistance. Gastroenterology 2004 ; 127 : 1678-84.
53. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000 ; 355 : 1745-50.
54. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003 ; 349 : 247-57.
55. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004 ; 126 : 394-401.
56. Jover R, Castells A, Llor X, Andreu M. Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006 ; 55 : 1819-20.
57. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorecral cancer. Gut 2006 ; 55 : 848-55.